FDA Appears to Pause Controversial Speedy Review Program and Complete Response Letter Disclosures
By Dr. Zubair Khalid, DVM, MS, PhD ·
The U.S. Food and Drug Administration has quietly shelved the Commissioner’s National Priority Voucher (CNPV) pilot program, according to a Reuters report cited by FierceBiotech. The CNPV program was designed to speed up review of certain drug applications. Separately, the agency also appears to have paused the practice of publishing complete response letters, the formal notices that explain why a drug application was rejected or needs more work. This pause follows a brief halt and subsequent resumption of the practice in July.
The FDA has not issued a public announcement about either action. The CNPV pilot program had been controversial since its launch, with critics questioning its transparency and potential for misuse. The complete response letters, which are typically posted on the FDA’s website after a decision, provide drug developers and investors with detailed reasons for a rejection. Their absence could leave companies and the public without clear insight into regulatory reasoning.
Why this matters for the life sciences
For biotech and pharmaceutical companies, both the CNPV program and the publication of complete response letters affect how drugs reach the market. The CNPV program offered a faster review pathway, and its suspension removes that option for developers of promising therapies. Meanwhile, the apparent pause in publishing complete response letters reduces transparency in the regulatory process. Without these letters, other companies cannot learn from past rejections, and investors may have less information to assess a drug’s chances. The FDA’s actions, whether temporary or permanent, could shift how companies plan their regulatory strategies and communicate with stakeholders.
Source: FDA appears to pause controversial speedy review program, complete response letter disclosures